SPINELLA, AMELIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.086
AS - Asia 6.036
EU - Europa 4.550
SA - Sud America 840
AF - Africa 156
OC - Oceania 24
Continente sconosciuto - Info sul continente non disponibili 12
Totale 21.704
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.811
SG - Singapore 1.814
CN - Cina 1.472
IT - Italia 1.355
GB - Regno Unito 940
HK - Hong Kong 673
BR - Brasile 638
VN - Vietnam 630
SE - Svezia 498
DE - Germania 411
BD - Bangladesh 395
FI - Finlandia 259
FR - Francia 255
RU - Federazione Russa 241
KR - Corea 212
IN - India 204
CA - Canada 149
ID - Indonesia 135
TR - Turchia 123
UA - Ucraina 99
AR - Argentina 76
BG - Bulgaria 76
MX - Messico 76
NL - Olanda 75
JP - Giappone 65
ES - Italia 63
ZA - Sudafrica 54
PL - Polonia 51
PK - Pakistan 44
IQ - Iraq 38
AT - Austria 35
MY - Malesia 33
CO - Colombia 31
IE - Irlanda 29
AE - Emirati Arabi Uniti 25
MA - Marocco 25
LT - Lituania 24
CL - Cile 23
AU - Australia 22
BE - Belgio 20
CZ - Repubblica Ceca 20
EC - Ecuador 19
VE - Venezuela 19
RO - Romania 18
EG - Egitto 17
SA - Arabia Saudita 16
IR - Iran 15
TN - Tunisia 15
PE - Perù 13
UZ - Uzbekistan 13
JO - Giordania 12
NP - Nepal 12
TW - Taiwan 12
AL - Albania 11
KE - Kenya 11
AZ - Azerbaigian 10
PH - Filippine 10
TH - Thailandia 10
EU - Europa 8
IL - Israele 8
OM - Oman 8
PT - Portogallo 8
PY - Paraguay 8
CR - Costa Rica 7
GR - Grecia 7
NG - Nigeria 7
PS - Palestinian Territory 7
BY - Bielorussia 6
BZ - Belize 6
DK - Danimarca 6
DZ - Algeria 6
GT - Guatemala 6
HU - Ungheria 6
RS - Serbia 6
UY - Uruguay 6
BH - Bahrain 5
CH - Svizzera 5
DO - Repubblica Dominicana 5
HN - Honduras 5
KG - Kirghizistan 5
SY - Repubblica araba siriana 5
EE - Estonia 4
ET - Etiopia 4
HR - Croazia 4
JM - Giamaica 4
LU - Lussemburgo 4
SK - Slovacchia (Repubblica Slovacca) 4
AO - Angola 3
BB - Barbados 3
BO - Bolivia 3
GE - Georgia 3
KZ - Kazakistan 3
LA - Repubblica Popolare Democratica del Laos 3
MD - Moldavia 3
MV - Maldive 3
PA - Panama 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BA - Bosnia-Erzegovina 2
Totale 21.658
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.195
Singapore 1.128
Ashburn 1.095
Fairfield 670
Hong Kong 663
San Jose 650
Chandler 592
Southend 470
Hefei 439
Council Bluffs 373
Woodbridge 321
Houston 312
Seattle 267
Nyköping 266
London 251
Beijing 230
Wilmington 223
New York 204
Cambridge 200
Ho Chi Minh City 196
Los Angeles 194
Helsinki 192
Seoul 191
The Dalles 166
Hanoi 163
Jacksonville 144
Milan 142
Ann Arbor 140
Chicago 133
Dearborn 133
San Diego 124
Bologna 114
Modena 113
Jakarta 110
Lauterbourg 85
Buffalo 80
Sofia 74
Princeton 71
Munich 70
Bremen 69
São Paulo 69
Shanghai 66
Orem 64
Atlanta 60
Moscow 59
Dallas 57
Frankfurt am Main 53
Izmir 51
Tokyo 50
Rome 46
Warsaw 42
Salt Lake City 40
Montreal 37
Parma 37
Denver 36
Florence 35
Johannesburg 35
Naples 35
Toronto 34
Redwood City 32
Mexico City 31
Poplar 30
Chennai 29
Phoenix 29
Turku 29
Eugene 28
Guangzhou 28
Haiphong 28
New Delhi 28
Reggio Emilia 28
Stockholm 28
Boardman 27
Columbus 26
Da Nang 26
Amsterdam 25
Ovada 25
Kent 24
Lappeenranta 24
Delhi 23
Ottawa 22
Mumbai 21
Nuremberg 21
Redondo Beach 21
Palermo 20
Paris 20
Portsmouth 20
Hillsboro 19
Rio de Janeiro 19
Brussels 18
San Francisco 18
Ankara 17
Brooklyn 17
Dublin 17
Falls Church 17
Elk Grove Village 16
Turin 16
Boston 15
Manchester 15
Philadelphia 15
Tampa 15
Totale 14.086
Salva come PNG Salva come JPEG
Nome #
Systemic sclerosis progression INvestiGation (SPRING) Italian registry: Demographic and clinico-serological features of the scleroderma spectrum 425
Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature 357
COVID-19 and rheumatic autoimmune systemic diseases: report of a large Italian patients series 353
Cryoglobulin evaluation: analysis of intra-laboratory and inter-laboratory variability 348
Established coronary artery disease in systemic sclerosis compared to type 2 diabetic female patients: a cross-sectional study 345
Cardiac involvement in systemic sclerosis: identification of high-risk patient profiles in different patterns of clinical presentation 343
Elevated Troponin Serum Levels in Adult Onset Still's Disease 341
Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 332
Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report 326
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 326
Serum 25-OH vitamin D levels in systemic sclerosis: analysis of 140 patients and review of the literature 324
Ultrasonography involvement of carotid, upper and lower limb arteries in a large cohort of systemic sclerosis patients 316
Unusual association between Budd–Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: a case report and review of the literature 315
The discrepancy between clinical and ultrasonographic remission in rheumatoid arthritis is not related to therapy or autoantibody status. 314
Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 303
Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF Therapy 302
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 285
Management of cardiopulmonary disease in patients with systemic sclerosis: cardiorheumatology clinic and patient care standardization proposal 281
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 271
Beyond cat scratch disease: a case report of bartonella infection mimicking vasculitic disorder 269
Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 269
Use of Neem oil and Hypericum perforatum for treatment of calcinosis-related skin ulcers in systemic sclerosis 259
The safety of iloprost in systemic sclerosis in a real-life experience 258
Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study 257
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers 255
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 253
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 252
Assessing hand grasp in patients with systemic sclerosis using the 16-grasp test: Preliminary results from a multidisciplinary study group 246
The prevalence of asymptomatic early sacroiliitis in Crohn’s disease patients: The single experience of an Italian tertiary care centre 246
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 239
Autologous fat grafting in the treatment of a scleroderma stump-skin ulcer: a case report 233
Procedural pain management in the treatment of scleroderma digital ulcers 232
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 230
AB0611 STRAIN ANALYSIS OF THE RIGHT VENTRICLE USING 2D-SPECKLE TRACKING ECHOCARDIOGRAPHY IN A COHORT OF PATIENTS WITH SYSTEMIC SCLEROSIS 230
DANCE CLASS DEDICATED TO SCLERODERMA PATIENTS: JOINT EVALUATION, FUNCTIONAL AND QUALITY OF LIFE BEFORE AND AFTER TREATMENT – CLINICAL TRIAL 227
PREVALENCE OF ULTRASOUND ABNORMALITIES IN PATIENTS WITH PSORIATIC ARTHRITIS IN A CLINICAL PHASE OF MINIMAL DISEASE ACTIVITY UNDER ANTI-TNF TREATMENT 223
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 221
Thu0349 autologous fat grafting in the treatment of patients with systemic sclerosis: current experience and future prospects 221
SEVERE VITAMIN D DEFICIENCY IN SYSTEMIC SCLEROSIS 220
Invited Response on: Comments on "Autologous Fat Grafting for the Oral and Digital Complications of Systemic Sclerosis: Results of a Prospective Study" 220
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 220
DIGITAL NECROSIS IN SYSTEMIC SCLEROSIS NOT ONLY A MICROVASCULAR DISEASE: A CASE REPORT 215
Peripheral Microangiopathy Changes in Pulmonary Arterial Hypertension Related to Systemic Sclerosis: Data From a Multicenter Observational Study 214
AB0645 CANNABINOIDS IN THE TREATMENT OF PAIN RELATED TO SYSTEMIC SCLEROSIS SKIN ULCERS: OUR EXPERIENCE 207
AB0724 Cardio-pulmonary disease management in patients with systemic sclerosis: cardio-rheumatology clinic and patient care standardisation proposal 207
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension 206
COVID-19 in Italian patients with rheumatic autoimmune systemic diseases 206
Promising use of filgotinib in patients affected by systemic sclerosis: Preliminary data from a case series of 5 patients 205
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients’ subgroups 204
Altered pathways of keratinization, extracellular matrix generation, angiogenesis, and stromal stem cells proliferation in patients with systemic sclerosis 203
Pulmonary arterial hypertension: Guidelines and unmet clinical needs 202
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 202
One-year clinical experience on the use of Nintedanib in Systemic Sclerosis 200
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 200
AB0760 Advanced oxidation protein products in serum of patients with systemic sclerosis: a possible indicator of clinical evolution 200
Management of Systemic Sclerosis Patients in the COVID-19 Era: The Experience of an Expert Specialist Reference Center 198
Living with arthritis: a “training camp” for coping with stressful events? A survey on resilience of arthritis patients following the COVID-19 pandemic 197
ORAL MANIFESTATIONS IN SYSTEMICSCLEROSIS: CLINICAL EVALUATION OF APERSONAL CASE SERIES OF 13 SCLERODERMAPATIENTS 195
Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers 193
Impegno cardiaco nella sclerosi sistemica 189
AB0212 LONG-TERM TREATMENT WITH RITUXIMAB IN SYSTEMIC SCLEROSISMANAGEMENT: AN OVERVIEW OF THE CLINICAL EXPERIENCE FROM A REAL-LIFE SETTING 185
THU0600 a case of systemic sclerosis complicated by renal crisis: potential etiopathogenetic role of cytomegalovirus and treatment 178
Cryofibrinogen: A possibile risk factor in systemic sclerosis 177
EFFICACY OF CERTOLIZUMAB PEGOL FOR DISEASE CONTROL OF PATIENTS AFFECTED BY ENTEROPATHIC SPONDYLARTHRITIS FOLLOWED BY THE JOINT GASTRO-RHEUMATOLOGICAL CLINIC 177
From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution 177
A New Promising Role for Selexipag in the Treatment of Scleroderma Vasculopathy: Preliminary Results From a Third Level Italian Scleroderma Center 175
Cryoproteinemia: new frontiers for clinicians and the laboratory 172
A CALL FOR A COMPREHENSIVE ROLE DEFINITION OF THE STUDY COORDINATOR IN RHEUMATOLOGICAL CLINICAL STUDIES 171
THE PREDICTIVE ROLE OF THE TAPSE/sPAP RATIO FOR CARDIOVASCULAR EVENTS AND MORTALITY IN SYSTEMIC SCLEROSIS COMPLICATED BY PULMONARY HYPERTENSION 170
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 170
IS THERE A DISSOCIATION BETWEEN CLINICAL REMISSION AND ULTRASONOGRAPHIC ASSESSMENT IN RHEUMATOID ARTHRITIS? 167
POS0837 THE USE OF CANNABIDIOL IN THE TREATMENT OF PAIN RELATED TO SCLERODERMA DIGITAL ULCERS 166
ACCERTAMENTO DELLA DISABILITÀ NELLE MALATTIE REUMATOLOGICHE (EX L.R. N.4 DEL 19 FEBBRAIO 2008) PROPOSTA DI PROTOCOLLO ORGANIZZATIVO 163
Organic-inorganic materials through first simultaneous frontal polymerization and frontal geopolymerization 159
Covid-19 vaccine hesitancy in systemic sclerosis 159
PROBABILITÀ DI SIEROCONVERSIONE DEL TEST QUANTIFERON DURANTE LA TERAPIA BIOTECNOLOGICA: DATI PRELIMINARI DI UNO STUDIO RETROSPETTIVO CONDOTTO PRESSO L’ARTHRITIS CLINIC DELL’AZIENDA OSPEDALIERO-UNIVERSITARIA POLICLINICO DI MODENA 158
Letters to the Editors 157
SAT0285 EVALUATION OF CHRONIC PAIN IN PATIENTS WITH SYSTEMIC SCLEROSIS COMPARED TO THOSE WITH CHRONIC HEADACHE AND RHEUMATOID ARTHRITIS 154
Erratum: Unusual association between Budd-Chiari syndrome secondary to antiphospholipid syndrome and relapsing polychondritis: A case report and review of the literature (Clinical Rheumatology (2013) 32 (905-907) DOI: 10.1007/s10067-013-2229-z) 153
Resilience of systemic sclerosis patients following the first COVID-19 wave in Italy 153
Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life 152
JANUS KINASES INHIBITORS IN CLINICAL PRACTICE IN ITALY. RESULTS FROM A SINGLE CENTER EXPERIENCE 150
Secondary cryofibrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study. 150
Real life use of prostacyclin analog (Iloprost), a multi-centric survey data from the scleroderma study group Emilia Romagna (Sclero-RER) and review of the literature 145
Secondary cryofbrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study 144
FRI0442 Long-term treatment with rituximab in interstitial lung disease related to systemic sclerosis: our clinical experience 143
Erratum: From Localized Scleroderma to Systemic Sclerosis: Coexistence or Possible Evolution (Dermatology Research and Practice (2018) 2018 (1284687) DOI: 10.1155/2018/1284687) 139
Role of COVID-19 in the progression of scleroderma interstitial lung disease and new onset pulmonary hypertension: a challenging case report. 137
Clinical and ultrasonographic predictors of disease activity after TNF-α inhibitor spacing in patients with psoriatic arthritis 133
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 131
BMP-4 and fetuin A in systemic sclerosis patients with or without calcinosis 131
L’IPERTENSIONE POLMONARE: DALLE NUOVE LINEE GUIDA ALLA PRATICA CLINICA 129
MYCOPHENOLATE MOFETIL TREATMENT REDUCES THE RISK OF TREATMENT ESCALATION DUE TO VASCULAR COMPLICATIONS IN LIMITED CUTANEOUS SYSTEMIC SCLEROSIS: EMULATION OF A TARGET TRIAL FROM ITALIAN RHEUMATOLOGY SOCIETY SPRING REGISTRY 125
Infections of scleroderma digital ulcers: A single center cohort retrospective study 122
OP0063 QUANTITATIVE COMPUTED TOMOGRAPHY PREDICTS 10-YEAR MORTALITY IN INTERSTITIAL LUNG DISEASE RELATED TO SYSTEMIC SCLEROSI 113
Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry. 109
The importance of body image and aesthetic medicine in systemic sclerosis 104
Significant nailfold capillary loss and late capillaroscopic pattern are associated with pulmonary arterial hypertension in systemic sclerosis 104
Prevalence and clinical relevance of digital ulcers in systemic sclerosis patients from the real-life: the experience of the SPRING Registry of the Italian Society for Rheumatology 100
From Raynaud Phenomenon to Systemic Sclerosis in COVID-19: A Case Report 95
Totale 21.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 85.544
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 85.544
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.565 86 64 109 127 75 130 45 108 175 136 326 184
2022/20231.671 216 207 116 147 205 210 69 151 220 25 53 52
2023/20241.162 42 69 52 168 204 91 91 111 31 40 98 165
2024/20254.633 139 77 91 311 851 734 369 268 532 215 413 633
2025/20269.328 618 317 633 1.104 1.366 622 1.130 435 853 890 816 544
2026/2027106 106 0 0 0 0 0 0 0 0 0 0 0
Totale 21.917